{
  "issued_date": "2011-02-16", 
  "original_url": "http://www.mhra.gov.uk/Publications/Safetywarnings/MedicalDeviceAlerts/CON108774", 
  "doc_details": {
    "Type": "Medical Device Alert", 
    "Series No": "MDA/2011/017", 
    "Audience": "Healthcare professionals", 
    "Published": "16 February 2011 at 14:30", 
    "Format": "Electronic only", 
    "Size": "A4", 
    "Pages": "4", 
    "Price": "Free", 
    "ISBN/ISSN": "", 
    "Author": "", 
    "Copyright": "Crown"
  }, 
  "_assets": [], 
  "body": "## Device\n\nBreast implants.\n\nAll types, makes and models.\n\n## Problem\n\nThere is uncertain evidence that women with breast implants may have a very small but increased risk of anaplastic large cell lymphoma (ALCL) of the breast.\n\nThe MHRA has not received any adverse incident reports identifying ALCL in association with breast implants in the UK. Discussions with the relevant UK professional bodies have not identified any cases.\n\nThe FDA recently published a Safety Communication entitled \u2018[FDA Medical Device Safety Communication: Reports of Anaplastic Large Cell Lymphoma (ALCL) in Women with Breast Implants\u2019](http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/BreastImplants/ucm239996.htm#summary)\u00a0(external link).\n\nIn a thorough review of scientific literature published from January 1997 to May 2010, the FDA identified 34 unique cases of ALCL in women with breast implants throughout the world. The FDA\u2019s adverse event reporting systems also contains 17 reports of ALCL in women with breast implants. This is a very small fraction of the 5-10 million women who have received breast implants worldwide.\n\nAnaplastic large cell lymphoma (ALCL) is a rare type of non-Hodgkin\u2019s lymphoma (NHL), a cancer involving the cells of the immune system. It is a very rare tumour in the breast, accounting for less than 1% of all breast malignancies.\n\nTo date there have been no corresponding reports of this disease association to the MHRA. The MHRA encourages all surgeons to report all adverse incidents, including cases of ALCL, to the adverse incident centre ([aic@mhra.gsi.gov.uk](mailto:aic@mhra.gsi.gov.uk)).\n\nThe MHRA will review any evidence that comes to light and take appropriate action as needed.\n\nThere is no indication for any routine action in the form of explantation or regular radiological examination including MRI. Women should be advised to self examine and consult their medical practitioner if they notice any changes in the breast or have any concerns.\n\n## Action  \n  \n  * No change to current best practice is needed.  \n  * If you are contacted by concerned women about this issue, reassure them that ALCL is a very rare form of cancer.  \n  * During initial consultation and subsequent follow-up examinations encourage women to self examine for changes in their breast and seek medical advice if concerned.  \n  * Report any confirmed cases of ALCL in women with breast implants to the MHRA.  \n  \n## Distribution\n\nThis MDA has been sent to:  \n  \n  * NHS trusts in England (Chief Executives)  \n  * HSC trusts in Northern Ireland (Chief Executives)  \n  * NHS boards in Scotland (Chief Executives)  \n  * NHS boards and trusts in Wales (Chief Executives)  \n  * Primary care trusts in England (Chief Executives)  \n  \nOnward distribution  \nPlease bring this notice to the attention of relevant employees in your establishment. Below is a suggested list of recipients.\n\nTrusts  \nCAS and SABS (NI) liaison officers for onward distribution to all relevant staff including:  \n  \n  * Directors of surgical units involved in breast reconstruction or augmentation  \n  * Medical directors  \n  * Nurse executive directors  \n  * Plastic surgeons and all surgeons involved in breast reconstruction or augmentation  \n  * Specialist nurses involved in breast cancer care  \n  \nPrimary care trusts  \nCAS liaison officers for onward distribution to all relevant staff including:  \n  \n  * General practitioners  \n  * Practice managers  \n  * Practice nurses  \n  \nIndependent distribution\n\nEstablishments registered with the Care Quality Commission (CQC) (England only)  \nThis alert should be read by:  \n  \n  * Breast augmentation centres  \n  * Hospitals in the independent sector  \n  * Independent treatment centres  \n  * Private medical practitioners  \n  \n## Feedback\n\nIf you have any comments or feedback on this Medical Device Alert, please email us at: [dts@mhra.gsi.gov.uk](mailto:dts@mhra.gsi.gov.uk)\u00a0\n\n## England\n\nIf you are in England, please send enquiries about this notice to the MHRA, quoting reference number MDA/2011/017 or 2011/002/002/291/003. \n\nTechnical aspects  \nBayode Adisa or Ian Smith  \nMedicines & Healthcare products Regulatory Agency  \nFloor 4  \n151 Buckingham Palace Road  \nLondon  \nSW1W 9SZ\n\nTel: 020 3080 7223 / 7306  \nFax: 020 8754 3965\n\nEmail: [bayode.adisa@mhra.gsi.gov.uk](mailto:bayode.adisa@mhra.gsi.gov.uk)\u00a0or\u00a0[ian.smith@mhra.gsi.gov.uk](mailto:ian.smith@mhra.gsi.gov.uk)\u00a0\n\nClinical aspects  \nDr Susanne Ludgate  \nMedicines & Healthcare products Regulatory Agency  \nFloor 4  \n151 Buckingham Palace Road  \nLondon  \nSW1W 9SZ\n\nTel: 020 3080 6800  \nFax: 020 8754 3965\n\nEmail: [susanne.ludgate@mhra.gsi.gov.uk](mailto:susanne.ludgate@mhra.gsi.gov.uk)\n\nHow to report adverse incidents  \nPlease report via our website: [Reporting adverse incidents involving medical devices](http://www.mhra.gov.uk/Safetyinformation/Reportingsafetyproblems/Devices/index.htm).  \nFurther information about CAS can be found on the [Central Alerting System website](https://www.cas.dh.gov.uk/Home.aspx) (external link).\n\n## Northern Ireland\n\nAlerts in Northern Ireland will continue to be distributed via the NI SABS system. \n\nEnquiries and adverse incident reports in Northern Ireland should be addressed to:  \n  \nNorthern Ireland Adverse Incident Centre  \nHealth Estates Investment Group  \nRoom 17  \nAnnex 6  \nCastle Buildings  \nStormont Estate  \nDundonald  \nBT4 3SQ\n\nTel: 02890 523 704  \nFax: 02890 523 900\n\nEmail: [NIAIC@dhsspsni.gov.uk](mailto:NIAIC@dhsspsni.gov.uk)\n\n[Northern Ireland Adverse Incident Centre (NIAIC)](http://www.dhsspsni.gov.uk/index/hea/niaic.htm) (external link)\n\nHow to report adverse incidents in Northern Ireland  \nPlease report directly to NIAIC, further information can be found on the [NIAIC website](http://www.dhsspsni.gov.uk/niaic) (external link).  \nFurther information about SABS can be found on the [SABS website](http://sabs.dhsspsni.gov.uk/NISABS/default.aspx?CATID=3) (external link).\n\n## Scotland\n\nEnquiries and adverse incident reports in Scotland should be addressed to: \n\nIncident Reporting and Investigation Centre  \nHealth Facilities Scotland  \nNHS National Services Scotland  \nGyle Square  \n1 South Gyle Crescent  \nEdinburgh  \nEH12 9EB\n\nTel: 0131 275 7575  \nFax: 0131 314 0722\n\nEmail: [nss.iric@nhs.net](mailto:nss.iric@nhs.net)\n\n## Wales\n\nEnquiries in Wales should be addressed to: \n\nDr Sara Hayes  \nSenior Medical Officer  \nMedical Device Alerts  \nWelsh Assembly Government  \nCathays Park  \nCardiff  \nCF10 3NQ\n\nTel: 029 2082 3922\n\nEmail: [Haz-Aic@wales.gsi.gov.uk](mailto:Haz-Aic@wales.gsi.gov.uk)\n", 
  "raw_html": "<div id=\"inner_tab_content\">\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t<h2 class=\"sw\">Device</h2><div class=\"content_section active_content_section\" id=\"Device\">\r\n\t\t\t\t\t\t\t\t<p><span>Breast implants.</span></p><p><span>All types, makes and models.</span></p>\r\n\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Problem</h2><div class=\"content_section\" id=\"Problem\">\r\n\t\t\t\t\t\t\t\t<p><span>There is uncertain evidence that women with breast implants may have a very small but increased risk of anaplastic large cell lymphoma (ALCL) of the breast.</span></p><p><span>The MHRA has not received any adverse incident reports identifying ALCL in association with breast implants in the UK. Discussions with the relevant UK professional bodies have not identified any cases.</span></p><p>The FDA recently published a Safety Communication entitled &#8216;<a href=\"http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/BreastImplants/ucm239996.htm#summary\" target=\"_blank\">FDA Medical Device Safety Communication: Reports of Anaplastic Large Cell Lymphoma (ALCL) in Women with Breast Implants&#8217;</a>&#160;(external link).</p><p>In a thorough review of scientific literature published from January 1997 to May 2010, the FDA identified 34 unique cases of ALCL in women with breast implants throughout the world. The FDA&#8217;s adverse event reporting systems also contains 17 reports of ALCL in women with breast implants. This is a very small fraction of the 5-10 million women who have received breast implants worldwide.</p><p>Anaplastic large cell lymphoma (ALCL) is a rare type of non-Hodgkin&#8217;s lymphoma (NHL), a cancer involving the cells of the immune system. It is a very rare tumour in the breast, accounting for less than 1% of all breast malignancies.</p><p>To date there have been no corresponding reports of this disease association to the MHRA. The MHRA encourages all surgeons to report all adverse incidents, including cases of ALCL, to the adverse incident centre (<a href=\"mailto:aic@mhra.gsi.gov.uk\">aic@mhra.gsi.gov.uk</a>).</p><p>The MHRA will review any evidence that comes to light and take appropriate action as needed.</p><p>There is no indication for any routine action in the form of explantation or regular radiological examination including MRI. Women should be advised to self examine and consult their medical practitioner if they notice any changes in the breast or have any concerns.</p>\r\n\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Action</h2><div class=\"content_section\" id=\"Action\">\r\n\t\t\t\t\t\t\t\t<ul>\r\n\t\t\t\t<li>No change to current best practice is needed.</li>\r\n\t\t\t\t<li>If you are contacted by concerned women about this issue, reassure them that ALCL is a very rare form of cancer.</li>\r\n\t\t\t\t<li>During initial consultation and subsequent follow-up examinations encourage women to self examine for changes in their breast and seek medical advice if concerned.</li>\r\n\t\t\t\t<li>Report any confirmed cases of ALCL in women with breast implants to the MHRA.</li></ul>\r\n\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Distribution</h2><div class=\"content_section\" id=\"Distribution\">\r\n\t\t\t\t\t\t\t\t<p>This MDA has been sent to:</p><ul>\r\n\t\t\t\t<li>NHS trusts in England (Chief Executives)</li>\r\n\t\t\t\t<li>HSC trusts in Northern Ireland (Chief Executives)</li>\r\n\t\t\t\t<li>NHS boards in Scotland (Chief Executives)</li>\r\n\t\t\t\t<li>NHS boards and trusts in Wales (Chief Executives)</li>\r\n\t\t\t\t<li>Primary care trusts in England (Chief Executives)</li></ul><p><font class=\"h3\">Onward distribution</font><br>Please bring this notice to the attention of relevant employees in your establishment. Below is a suggested list of recipients.</p><p><font class=\"h4\">Trusts</font><br>CAS and SABS (NI) liaison officers for onward distribution to all relevant staff including:</p><ul>\r\n\t\t\t\t<li>Directors of surgical units involved in breast reconstruction or augmentation</li>\r\n\t\t\t\t<li>Medical directors</li>\r\n\t\t\t\t<li>Nurse executive directors</li>\r\n\t\t\t\t<li>Plastic surgeons and all surgeons involved in breast reconstruction or augmentation</li>\r\n\t\t\t\t<li>Specialist nurses involved in breast cancer care</li></ul><p><font class=\"h4\">Primary care trusts</font><br>CAS liaison officers for onward distribution to all relevant staff including:</p><ul>\r\n\t\t\t\t<li>General practitioners</li>\r\n\t\t\t\t<li>Practice managers</li>\r\n\t\t\t\t<li>Practice nurses</li></ul><p><font class=\"h3\">Independent distribution</font></p><p><font class=\"h4\">Establishments registered with the Care Quality Commission (CQC) (England only)</font><br>This alert should be read by:</p><ul>\r\n\t\t\t\t<li>Breast augmentation centres</li>\r\n\t\t\t\t<li>Hospitals in the independent sector</li>\r\n\t\t\t\t<li>Independent treatment centres</li>\r\n\t\t\t\t<li>Private medical practitioners</li></ul>\r\n\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Feedback</h2><div class=\"content_section\" id=\"Feedback\">\r\n\t\t\t\t\t\t\t\t<p>If you have any comments or feedback on this Medical Device Alert, please email us at: <a href=\"mailto:dts@mhra.gsi.gov.uk\">dts@mhra.gsi.gov.uk</a>&#160;</p>\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t<h2 class=\"sw\">England</h2><div class=\"content_section\" id=\"England\">\r\n\t\t\t\t\t\t\t\t\tIf you are in England, please send enquiries about this notice to the MHRA, quoting reference number <span>MDA/2011/017</span> or <span>2011/002/002/291/003</span>. <p><span>Technical aspects</span><br>Bayode Adisa or Ian Smith<br>Medicines &amp; Healthcare products Regulatory Agency<br>Floor 4<br>151 Buckingham Palace Road<br>London<br>SW1W 9SZ</p><p>Tel: 020 3080 7223 / 7306<br>Fax: 020 8754 3965</p><p>Email: <a href=\"mailto:bayode.adisa@mhra.gsi.gov.uk\">bayode.adisa@mhra.gsi.gov.uk</a>&#160;or&#160;<a href=\"mailto:ian.smith@mhra.gsi.gov.uk\">ian.smith@mhra.gsi.gov.uk</a>&#160;</p><p><span>Clinical aspects</span><br>Dr Susanne Ludgate<br>Medicines &amp; Healthcare products Regulatory Agency<br>Floor 4<br>151 Buckingham Palace Road<br>London<br>SW1W 9SZ</p><p>Tel: 020 3080 6800<br>Fax: 020 8754 3965</p><p>Email: <a href=\"mailto:susanne.ludgate@mhra.gsi.gov.uk\">susanne.ludgate@mhra.gsi.gov.uk</a></p><p><font class=\"h3\">How to report adverse incidents</font><br>Please report via our website: <a href=\"http://www.mhra.gov.uk/Safetyinformation/Reportingsafetyproblems/Devices/index.htm\">Reporting adverse incidents involving medical devices</a>.<br>Further information about CAS can be found on the <a href=\"https://www.cas.dh.gov.uk/Home.aspx\">Central Alerting System website</a> (external link).</p>\r\n\t\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Northern Ireland</h2><div class=\"content_section\" id=\"Northern Ireland\">\r\n\t\t\t\t\t\t\t\t\tAlerts in Northern Ireland will continue to be distributed via the NI SABS system. <p>Enquiries and adverse incident reports in Northern Ireland should be addressed to:<br><br>Northern Ireland Adverse Incident Centre<br>Health Estates Investment Group<br>Room 17<br>Annex 6<br>Castle Buildings<br>Stormont Estate<br>Dundonald<br>BT4 3SQ</p><p>Tel: 02890 523 704<br>Fax: 02890 523 900</p><p>Email: <a href=\"mailto:NIAIC@dhsspsni.gov.uk\">NIAIC@dhsspsni.gov.uk</a></p><p><a href=\"http://www.dhsspsni.gov.uk/index/hea/niaic.htm\" target=\"_blank\">Northern Ireland Adverse Incident Centre (NIAIC)</a> (external link)</p><p><font class=\"h3\">How to report adverse incidents in Northern Ireland</font><br>Please report directly to NIAIC, further information can be found on the <a href=\"http://www.dhsspsni.gov.uk/niaic\" target=\"_blank\">NIAIC website</a> (external link).<br>Further information about SABS can be found on the <a href=\"http://sabs.dhsspsni.gov.uk/NISABS/default.aspx?CATID=3\" target=\"_blank\">SABS website</a> (external link).</p>\r\n\t\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Scotland</h2><div class=\"content_section\" id=\"Scotland\">\r\n\t\t\t\t\t\t\t\t\tEnquiries and adverse incident reports in Scotland should be addressed to: <p>Incident Reporting and Investigation Centre<br>Health Facilities Scotland<br>NHS National Services Scotland<br>Gyle Square<br>1 South Gyle Crescent<br>Edinburgh<br>EH12 9EB</p><p>Tel: 0131 275 7575<br>Fax: 0131 314 0722</p><p>Email: <a href=\"mailto:nss.iric@nhs.net\">nss.iric@nhs.net</a></p>\r\n\t\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Wales</h2><div class=\"content_section\" id=\"Wales\">\r\n\t\t\t\t\t\t\t\t\tEnquiries in Wales should be addressed to: <p>Dr Sara Hayes<br>Senior Medical Officer<br>Medical Device Alerts<br>Welsh Assembly Government<br>Cathays Park<br>Cardiff<br>CF10 3NQ</p><p>Tel: 029 2082 3922</p><p>Email: <a href=\"mailto:Haz-Aic@wales.gsi.gov.uk\">Haz-Aic@wales.gsi.gov.uk</a></p>\r\n\t\t\t\t\t\t\t\t</div>\r\n</div>\r\n\t\t\t", 
  "title": "Medical Device Alert: All types, makes and models of breast implants (MDA/2011/017)", 
  "alert_type": [
    "devices"
  ], 
  "medical_specialism": [
    "cosmetic-surgery", 
    "general-practice", 
    "radiology"
  ]
}